Clinical and Laboratory Factors Associated with Severe Disease Course in Turkish Patients with SARS-COV-2 Infection

IRCMJ logo

Keywords

COVID-19
Risk factors of severe pneumonia
SARS-COV-2
Severe disease

How to Cite

ak, çağatay, sayar, süleyman, polat, zeynep pelin, tarıkçı kılıç, ebru, & özdil, kamil. (2021). Clinical and Laboratory Factors Associated with Severe Disease Course in Turkish Patients with SARS-COV-2 Infection. Iranian Red Crescent Medical Journal, 23(2). https://doi.org/10.32592/ircmj.2021.23.2.283

Abstract

Background: Coronavirus disease 2019 (COVID-19) can demonstrate different clinical spectra.

Objectives: The current study aimed to analyze the clinical and laboratory risk factors of the severe course of disease in patients with COVID-19.

Materials and Methods: Consecutive patients with a diagnosis of COVID-19 pneumonia were included in the present study. The demographic characteristics, comorbid diseases, symptoms, chest computed tomography (CT) findings, laboratory data, oxygen saturation (SpO2), and body temperature of the patients were recorded. The coexistence of pulmonary infiltration in CT and SpO2 of ≤ %93 on fingertip pulse oximeter was defined as the severe course of the disease.

Results: A total of 475 patients were included in the current study. The mean age of the patients was 52.02±15.9 years, and 259 (54.5%) participants were male. The disease was mild and severe in 80% (n=380) and 20% (n=95) of the patients. The age of > 50 years, coexistence of hypertension (HT) and diabetes mellitus (DM), neutrophil/lymphocyte ratio (NLR) of > 4, high lactate dehydrogenase (LDH) of > 240 U/L, C-reactive protein (CRP) of > 8 mg/dL, and D-dimer of ≥ 1000 ng/mL were determined to be the risk factors for the severe course of the disease.

Conclusion: Age, NLR, CRP, LDH, D-dimer, comorbidity, and coexistence of DM and HT were the independent risk factors for the severe course of the disease. The aforementioned factors should be taken into account during risk stratification and management of patients with COVID-19.

https://doi.org/10.32592/ircmj.2021.23.2.283

References

  1. Soy M, Keser G, Atagündüz P, Tabak F, Atagündüz I, Kayhan S, et al. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol. 2020;39(7):2085-94. doi: 10.1007/s10067-020-05190-5. [PubMed: 32474885].
  2. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536-44. doi: 10.1038/s41564-020-0695-z. [PubMed: 32123347].
  3. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. doi: 10.1016/S0140-6736(20)30566-3. [PubMed: 32171076].
  4. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239-42. doi: 10.1001/jama.2020.2648. [PubMed: 32091533].
  5. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. J Virol. 2020;94(7):e00127-20. doi: 10.1128/JVI.00127-20. [PubMed: 31996437].
  6. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239-42. doi: 10.1001/jama.2020.2648. [PubMed: 32091533].
  7. Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20(4):400-2. doi: 10.1016/S1473-3099(20)30132-8. [PubMed: 32113509].
  8. Xu Z, Shi L, Wang Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420-2. doi: 10.1016/S2213-2600(20)30076-X. [PubMed: 32085846].
  9. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71(15):762-8. doi: 10.1093/cid/ciaa248. [PubMed: 32161940].
  10. Opal SM, Girard TD, Ely EW. The immunopathogenesis of sepsis in elderly patients. Clin Infect Dis. 2005;41(Suppl 7):S504-12. doi: 10.1086/432007. [PubMed: 16237654].
  11. Tadic M, Cuspidi C, Mancia G, Dell'Oro R, Grassi G. COVID-19, hypertension and cardiovascular diseases: should we change the therapy? Pharmacol Res. 2020;158:104906. doi: 10.1016/j.phrs.2020.104906. [PubMed: 32461198].
  12. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. China medical treatment expert group for covid-19. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547. doi: 10.1183/13993003.00547-2020. [PubMed: 32217650].
  13. Chen Y, Gong X, Wang L, Guo J. Effects of hypertension, diabetes and coronary heart disease on COVID-19 diseases severity: a systematic review and meta-analysis. MedRxiv. 2020;3:1-12. doi: 10.1101/2020.03.25.20043133.
  14. Lippi G, Wong J, Henry BM. Hypertension in patients with coronavirus disease 2019 (COVID-19): a pooled analysis. Pol Arch Intern Med. 2020;130(4):304-9. doi: 10.20452/pamw.15272. [PubMed: 32231171].
  15. Izcovich A, Ragusa MA, Tortosa F, LavenaMarzio MA, Agnoletti C, Bengolea A, et al. Prognostic factors for severity and mortality in patients infected with COVID-19: a systematic review. PLoS One. 2020;15(11):e0241955. doi: 10.1371/journal.pone.0241955. [PubMed: 33201896].
  16. Feng X, Li S, Sun Q, Zhu J, Chen B, Xiong M, et al. Immune-inflammatory parameters in COVID-19 cases: a systematic review and meta-analysis. Front Med (Lausanne). 2020;7:301. doi: 10.3389/fmed.2020.00301. [PubMed: 32582743].
  17. Xiang N, Havers F, Chen T, Song Y, Tu W, Li L, et al. Use of national pneumonia surveillance to describe influenza A(H7N9) virus epidemiology, China, 2004-2013. Emerg Infect Dis. 2013;19(11):1784-90. doi: 10.3201/eid1911.130865. [PubMed: 24206646].
  18. Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med. 2020;18(1):206. doi: 10.1186/s12967-020-02374-0. [PubMed: 32434518].
  19. Di Micco P, Russo V, Carannante N, Imparato M, Rodolfi S, Cardillo G, et al. Clotting factors in COVID-19: epidemiological association and prognostic values in different clinical presentations in an Italian cohort. J Clin Med. 2020;9(5):1371. doi: 10.3390/jcm9051371. [PubMed: 32392741].
  20. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020;81(2):e16-25. doi: 10.1016/j.jinf.2020.04.021. [PubMed: 32335169].